TCT 2022 will feature late-breaking clinical science presenting the safety and effectiveness of minimally invasive techniques, pharmaceuticals, technologies, and devices for treating or preventing cardiovascular disease. The event takes place September 16-19 in Boston at the Boston Convention and Exhibition Center.
The TCT MedTech Innovation Forum brings together clinicians, entrepreneurs, investors, payors, and regulators to identify clinical challenges and opportunities for innovation in cardiovascular care. The forum aims to shape the future of patient care through informed discussion and real-world insight.
The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature 12 studies as Late-Breaking Clinical Science and Featured Clinical Research. These studies highlight advances in transcatheter aortic valve replacement, mitral, tricuspid, and left atrial appendage occlusion therapies.
The TVT 2022 program features cutting-edge research on transcatheter aortic valve replacement (TAVR) and other structural heart therapies. The meeting will focus on patient evaluation, imaging modalities, and therapeutic options.
The annual conference will cover important themes such as decision-making in coronary revascularization, specific treatment of complex lesion subsets, and the use of adjunctive tools. CTO Plus 2022 will feature 12 live case transmissions performed by world-class faculty members.
The Cardiovascular Research Foundation (CRF) will host THT 2022 from February 1-2, 2022. The conference features new and emerging treatments for heart failure, including transcatheter approaches and innovative monitoring strategies.
A new study published in The New England Journal of Medicine found that percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) did not meet noninferiority for one-year outcomes compared to bypass surgery. However, FFR-guided PCI performed favorably in patients with low SYNTAX scores and less complex disease.
A randomized trial comparing plug-based and suture-based vascular closure techniques after TAVR found that the plug-based technique had a shorter time to hemostasis but higher access-site complications. The study, CHOICE-CLOSURE, reported similar mortality rates between both groups.
The SWISS-APERO Trial compared Amulet with Watchman FLX devices for percutaneous left atrial appendage closure. Both devices achieved similar LAA occlusion rates at 45 days, but with different mechanisms. However, Amulet was associated with higher procedural complications and lower peridevice leak rates than Watchman FLX.
A study published in The Lancet found that using physiologic measurement quantitative flow ratio (QFR) for lesion selection during percutaneous coronary intervention (PCI) leads to better clinical outcomes compared to standard angiography-guided strategies. This is due to fewer procedural complications and superior long-term results.
The OPT-PEACE trial found that dual antiplatelet therapy (DAPT) followed by single anti-platelet therapy (SAPT) results in less gastrointestinal mucosal findings than continued DAPT. SAPT also reduces clinical GI bleeding and new ulcers compared to DAPT.
Patients with diabetes undergoing percutaneous coronary intervention (PCI) have lower target lesion failure rates with amphilimus-eluting stents compared to zotarolimus-eluting stents. At one year, amphilimus-eluting stents met the criteria for noninferiority and superiority over zotarolimus-eluting stents.
The VOYAGER PAD trial found that drug-coated devices do not increase mortality risk in patients with peripheral artery disease. Rivaroxaban use consistently reduced ischemic limb and cardiovascular outcomes regardless of device type.
The OPTIMIZE trial found that the new stent did not meet non-inferiority criteria due to high TVMI rates from high-sensitivity troponin biomarkers. However, independent analyses demonstrate non-inferiority with comparable relative non-inferiority margin, suggesting potential for improved clinical outcomes
A randomized trial comparing a nano-coated coronary stent with shorter dual anti-platelet therapy (DAPT) to a drug-eluting stent (DES) with guideline-recommended DAPT duration found no reduction in bleeding or thrombotic events. The study included 996 patients and found the rate of bleeding in the test group was 7.5% compared to 8.9% i...
A randomized trial found that durable polymer drug-eluting stents are non-inferior to biodegradable polymers in patients with acute coronary syndrome, with a higher risk of device-oriented composite endpoint. The study suggests improved outcomes for patients with significant coronary stenosis and eligible for stent implantation.
The DEFINE-FLOW study found that vessels with abnormal FFR (<0.8) but intact CFR (>=2.0) do not have non-inferior outcomes compared to those with normal FFR and CFR when treated medically. The study's results suggest that invasive CFR assessment may not be necessary for lesions with preserved coronary flow reserve.
OnSight Medical's AI-based software provides real-time expert-level scans with high-quality 4D images, enhancing access to cardiac ultrasound in underserved populations. The company won the TCT Connect 2020 Shark Tank Innovation Competition and received a $200,000 award from the Jon DeHaan Foundation.
The TARGET FFR trial found that a physiology-guided incremental optimization strategy (PIOS) reduced the proportion of patients with a final post-PCI FFR ?0.80, while also improving mean Coronary Flow Reserve. The study's results suggest potential benefits for PCI outcomes.
The FORECAST trial found that fractional flow reserve derived from computed tomography coronary angiography (FFRCT) reduced the use of invasive coronary angiography by 22% without significantly reducing costs. The strategy also showed promise in terms of reducing healthcare utilization and improving patient outcomes.
The REFLECT II trial evaluated the safety and effectiveness of TriGuard 3, a self-stabilizing cerebral embolic deflection filter, in patients undergoing TAVR. The device met the primary safety endpoint, but did not demonstrate superiority for reducing ischemic stroke or larger lesions.
A new self-expanding bioprosthetic valve used in TAVR failed to demonstrate non-inferiority compared to an existing valve. The SCOPE II Trial found increased rates of cardiac death and moderate-severe aortic regurgitation with the new valve.
The MITHRAS trial found that interventional closure of an iatrogenic atrial septal defect (iASD) driven by transcatheter mitral valve repair was not superior to conservative medical treatment. The study also revealed that the presence of a persistent iASD is associated with increased long-term mortality and morbidity following TMVR.
The COMBINE (OCT-FFR) trial found that the presence of TCFA is a strong predictor of future MACE, despite lack of ischemia. Combining FFR and OCT can improve accuracy of high-risk lesion identification in patients with diabetes.
The study found that lipid-rich plaques detected by NIRS imaging are associated with adverse outcomes and can be used as a prognostic index for vulnerable plaques. High-risk plaques were identified in patients with recent myocardial infarction, and their presence was linked to increased risk of future cardiac events.
The PROSPECT ABSORB trial found PCI safe with favorable long-term outcomes for non-flow-limiting vulnerable plaques. Follow-up lumen areas were substantially enlarged in BVS-treated lesions compared to GDMT alone.
A meta-analysis of bivalirudin versus heparin in patients with myocardial infarction (MI) found that bivalirudin was associated with similar overall rates of 30-day mortality but lower rates of serious bleeding. In STEMI patients, bivalirudin use reduced all-cause mortality and serious bleeding.
Research from the Cardiovascular Research Foundation will present latest data on PCI, imaging technologies, and TAVR at ACC.19. The study found that treatment with angiotensin-converting enzyme inhibitors or receptor blockers affects revascularization after percutaneous coronary intervention.
The BIONYX trial found that the Resolute Onyx stent is safe and effective in a complex patient population, with low rates of cardiac death and target vessel-related myocardial infarction. The stent's improved radiographic visibility facilitates accurate assessment of stent expansion and apposition to the arterial wall.
The ReCre8 trial found that a novel polymer-free amphilimus-eluting stent was clinically safe and effective, comparable to a durable polymer zotarolimus-eluting stent. The study showed that one-month DAPT in troponin-negative patients may be safe regarding stent thrombosis.
The Lipid-Rich Plaque (LRP) study found a significant correlation between non-flow-limiting lipid-rich plaques detected by NIRS-IVUS and the development of major adverse cardiac events. The study showed that patients with higher maxLCBI4mm values had a higher risk of experiencing non-culprit MACE events within 24 months.
The OAC-ALONE study found that oral anticoagulation (OAC) alone did not provide non-inferiority to combined OAC and antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond one year after stent implantation. The study also found higher rates of major bleeding with OAC alone.
A multicenter study found that IVUS guidance over angiography guidance during DES implantation reduces target vessel failure by lowering the rate of TVF at one year. The ULTIMATE trial showed improved clinical outcomes, particularly for patients who had an IVUS-defined optimal procedure.
The COAPT trial found that the MitraClip device significantly reduced hospitalization rates and mortality, while improving quality-of-life measures and functional capacity in heart failure patients with secondary mitral regurgitation. The study also showed a substantial reduction in the need for heart transplants or left ventricular as...
The SOLVE-TAVI trial found that local anesthesia is both safe and effective for patients undergoing transcatheter aortic valve replacement (TAVR), especially those with intermediate to high surgical risk. The study also showed similar outcomes between current-generation balloon-expandable and self-expanding valves.
A novel index of coronary artery stenosis severity called resting full-cycle ratio (RFR) has been found to be diagnostically equivalent to instantaneous wave-free ratio (iFR). The study, presented at EuroPCR, suggests RFR could identify pressure-based stenosis severity independent of timing within the cardiac cycle.
The DAPT STEMI trial found that six months of dual antiplatelet therapy was non-inferior to twelve months in STEMI patients receiving drug-eluting stents, questioning the need for extended duration DAPT. The study's results suggest that STEMI patients may not benefit from prolonged DAPT therapy beyond six months.
The SENIOR trial found that a Synergy bioabsorbable polymer DES with shorter dual antiplatelet therapy (DAPT) is more effective than a bare-metal stent in elderly patients. This new strategy reduces adverse events without increasing bleeding risk, suggesting a change in recommended PCI strategies for this age group.
The REDUCE trial found no difference in all-cause mortality, myocardial infarction, and stent thrombosis between three and 12 months of DAPT. Major bleeding rates were similar among treatment arms, but overall mortality rates differed slightly at 1.9% vs 0.8%
The DKCRUSH-V trial found that the double kissing crush two-stent technique resulted in a lower rate of target lesion failure compared to provisional stenting at one year. The study also showed improved outcomes for patients with true distal left main bifurcation lesions.
The ABSORB IV trial found that biosorbable stents are non-inferior to traditional metal stents, but still require further advancements in device technology and technique. The study demonstrated a lower rate of device thrombosis with improved pre-dilatation and post-dilatation techniques.
Researchers found TAVR to be highly cost-effective compared to SAVR in intermediate surgical risk patients with aortic stenosis. Over two years, follow-up costs were substantially lower with TAVR than SAVR, resulting in lifetime cost savings and improved quality-adjusted life expectancy.
The CULPRIT-SHOCK trial found that culprit lesion only percutaneous coronary intervention (PCI) reduces the composite of 30-day mortality and/or severe renal failure in patients with multivessel disease and cardiogenic shock. Immediate multivessel PCI was associated with higher rates of adverse outcomes.
Patients with left main coronary artery disease (LMCAD) who underwent percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) showed similar quality of life improvements at three years. PCI demonstrated a greater early benefit, with improved health status measures that were sustained over time.
Dr. Alec Vahanian, MD, is recognized for advancing the field of interventional cardiovascular medicine through technical expertise and innovation. He has performed pioneering procedures, including percutaneous mitral commissurotomy and transcatheter aortic valve replacement.
Renowned cardiologist Elazer Edelman, MD, PhD, will be recognized for his contributions to the development of coronary stents and vascular disease research. He has authored nearly 300 scientific publications and mentored over 350 graduate students.
A study presented at TCT 2016 found the Watchman device had a successful procedure rate of 95.6% with low major complications, including pericardial effusion and embolization. New operators performed 50% of procedures, yet complication rates remained favorable.
A large-scale multicenter prospective study found that PCI on coronary artery lipid-rich plaque (LRP) detected by near infrared spectroscopy (NIRS) was not associated with subsequent major adverse cardiac events (MACE). The study suggests that NIRS-defined LRP is a safe and stable condition, contrary to previous autopsy-based studies.
The PLATINUM DIVERSITY trial found that women and minorities had higher rates of death and myocardial infarction after coronary stent procedures compared to white men. The study also highlighted the need for further research into the causes of these observed gradients of risk.
The SENTINEL trial found that the Sentinel device was safe during TAVR but did not meet its primary efficacy endpoint of reducing median new lesion volume on MRI. Despite this, embolic protection resulted in a reduction of new lesion volume after adjusting for confounders.